Last edition
News about "Akeso "
Akeso and Inovio Pharmaceuticals Partner to Develop Combination Therapy for Glioblastoma
Akeso and Inovio Pharmaceuticals have entered into a clinical collaboration to evaluate cadonilimab with INO-5412 in glioblastoma. The combination will be studied in the phase-II INSIGhT trial sponsored by Dana-Farber Cancer Institute, building on prior positive data.
Akeso | 05/03/2026 | By Akanki
China's NMPA Accepts Akeso's Gumukimab sNDa for Ankylosing Spondylitis
China’s NMPA gives approval to Akeso’s gumokimab for the treatment of active ankylosing spondylitis, supported by Phase III data showing significant symptom relief and functional improvement.
Akeso | 20/01/2026 | By News Bureau | 198
China Updates Ivonescimab Label After NSCLC Survival Gains
China’s drug regulator has approved a label update for Akeso’s ivonescimab, citing Phase III data showing significant improvements in progression-free and overall survival in EGFR-TKI-resistant non-small cell lung cancer patients.<br />
Akeso | 07/01/2026 | By News Bureau | 370
US FDA Approves Phase III Trial of Cadonilimab Against Nivolumab in Gastric Cancer
The FDA’s clearance enables a global phase III study evaluating Cadonilimab, in combination with chemotherapy, as a first-line option for HER2-negative, unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma, directly comparing its efficacy to standard chemotherapy with or without Nivolumab.
Akeso | 12/12/2025 | By Akanki | 293
Akeso Doses First Patient in Global Trial of Cadonilimab for PD-1 Resistant Liver Cancer
COMPASSION-36, the first global Phase III trial of Cadonilimab, is underway in China, the US, and Europe. It marks a key step in Akeso's effort to advance cancer immunotherapy beyond single-target treatments.
Akeso | 15/09/2025 | By Dineshwori | 227
Akeso Gets NMPA Approval of Penpulimab for Nasopharyngeal Cancer
With this new approval, penpulimab now provides comprehensive treatment coverage across all stages of NPC, offering patients a continuous immunotherapy option from first-line to third-line therapy.
Akeso | 17/03/2025 | By Aishwarya | 470
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy